Relypsa, Inc.

Scott Garland, former exec at Relypsa Inc. , Exelixis Inc. and Genentech Inc. , has his work cut out in his new role as CEO of Portola Pharmaceuticals Inc. in turning around performance of the c

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

Vifor Pharma Group ’s novel hyperkalemia therapy, Veltassa (patiromer), should be available in the EU in the coming months, with the timing and sequencing of launches dependent on market access eva

Venture capital investors put $2.2bn into 128 biopharmaceutical companies in the first quarter of this year and at the rate that VC firms are raising new funds, 2017 could be another big financing yea